Drug repurposing for Parkinson's disease has emerged as a critical strategy to accelerate the development of disease-modifying therapies. Multiple international consortia, patient organizations, and research networks have been established to identify, evaluate, and advance existing drugs for Parkinson's treatment. This page provides an overview of the major consortia and their collaborative efforts.
Lead: Cure Parkinson's (UK)
An international clinical trials program that has reviewed over 200 compounds and advanced 30+ repurposed drugs into clinical trials. The program brings together leading researchers, pharmaceutical companies, and people with Parkinson's to accelerate disease-modifying therapies.
Lead: Parkinson's UK (UK)
A systematic drug screening initiative focusing on approved drugs with potential neuroprotective effects in Parkinson's. The program leverages a network of UK research centers and patient cohorts.
A coordinated federal initiative leveraging NIH resources to identify and test existing drugs for Parkinson's. The program supports preclinical screening, clinical trials, and biomarker development.
Lead: Michael J. Fox Foundation (USA)
The world's largest nonprofit funder of Parkinson's research, supporting a comprehensive therapeutic development pipeline including drug repurposing programs.
A network of academic medical centers collaborating on clinical trials across multiple countries, facilitating rapid patient recruitment and data sharing.
| Region | Countries | Trial Centers |
|---|---|---|
| Europe | UK, Germany, France, Spain | 25+ |
| North America | USA, Canada | 30+ |
| Asia-Pacific | Australia, Japan | 10+ |
Genetic stratification programs focusing on specific PD subtypes:
| Drug | Original Indication | Mechanism | Consortia |
|---|---|---|---|
| Exenatide | Diabetes | GLP-1R agonist | LCT, NIH, MJFF |
| Ambroxol | Mucolytic | GBA enhancer | LCT, Drug Club |
| Inosine | Gout | Urate elevation | LCT, NIH |
| Nilotinib | Leukemia | Autophagy inducer | LCT, NIH |
| Simvastatin | Cholesterol | Neuroprotection | Drug Club, NIH |
| Metformin | Diabetes | AMPK activator | NIH, MJFF |
Many consortia operate through partnerships with pharmaceutical companies:
All major consortia incorporate patient involvement:
| Achievement | Impact |
|---|---|
| Exenatide Phase II success | First positive GLP-1 trial in PD |
| Ambroxol GBA program | First targeted therapy for GBA-PD |
| Inosine SPRING trial | Largest urate elevation study |
| Patient registries | Rapid recruitment for trials |
Total investment in PD drug repurposing across consortia:
The Critical Path for Parkinson's (CPP) consortium, formerly known as the Parkinson's Disease CONSORTIUM, is a public-private partnership focused on accelerating PD therapeutic development through biomarker development and clinical trial optimization[1].
Key Activities:
The Synuclein Imaging as a Diagnostic Marker for Parkinson's Disease (STEADY) program investigates biomarkers for PD diagnosis and progression[2].
Focus Areas:
The PD TRA coordinates clinical trial data sharing and patient recruitment across international sites[3].
Contributions:
Lundbeck has conducted multiple Phase III trials for PD drug repurposing, including investigative therapies targeting alpha-synuclein aggregation[4].
Notable Programs: